VIVO Stock Recent News
VIVO LATEST HEADLINES
FORT MILL, SC / ACCESSWIRE / October 2, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a company dedicated in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced several updates for their VIVO non-invasive mapping system. Over the last 60 days and through the month of October the company has participated in several industry meetings where VIVO has been or will be highlighted.
FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of origin of ventricular tachycardia (VT) for patients with scar related re-entrant VT were presented. Additionally, the presentation showed the relationship to the relevant myocardial scar on cross-sectional imaging from the CT scan.
FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.
FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial evaluation of the VIVO product was completed earlier this year at Hamad Medical Corporation Heart Hospital in Doha.
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.
Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.
100% technical buy signals. 8 new highs and up 15.79% in the last month.
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.